MX2022005563A - Ligandos de la pseudoquinasa tyk2. - Google Patents
Ligandos de la pseudoquinasa tyk2.Info
- Publication number
- MX2022005563A MX2022005563A MX2022005563A MX2022005563A MX2022005563A MX 2022005563 A MX2022005563 A MX 2022005563A MX 2022005563 A MX2022005563 A MX 2022005563A MX 2022005563 A MX2022005563 A MX 2022005563A MX 2022005563 A MX2022005563 A MX 2022005563A
- Authority
- MX
- Mexico
- Prior art keywords
- ligands
- tyk2 pseudokinase
- tyk2
- pseudokinase ligands
- disorders
- Prior art date
Links
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 title abstract 3
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En este documento se describen ligandos de la pseudoquinasa TYK2 y métodos para utilizar ligandos de la pseudoquinasa TYK2 en el tratamiento de enfermedades, trastornos o afecciones. También se describen en este documento composiciones farmacéuticas que contienen tales compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933179P | 2019-11-08 | 2019-11-08 | |
| US202063046514P | 2020-06-30 | 2020-06-30 | |
| PCT/US2020/059210 WO2021092246A1 (en) | 2019-11-08 | 2020-11-05 | Tyk2 pseudokinase ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005563A true MX2022005563A (es) | 2022-08-19 |
Family
ID=75846491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005563A MX2022005563A (es) | 2019-11-08 | 2020-11-05 | Ligandos de la pseudoquinasa tyk2. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11753411B2 (es) |
| EP (1) | EP4054581A4 (es) |
| JP (1) | JP7635228B2 (es) |
| KR (1) | KR20220107194A (es) |
| CN (1) | CN114929226B (es) |
| AU (1) | AU2020378345A1 (es) |
| BR (1) | BR112022008821A2 (es) |
| CA (1) | CA3160637A1 (es) |
| CL (1) | CL2022001178A1 (es) |
| CO (1) | CO2022007814A2 (es) |
| IL (1) | IL292785B2 (es) |
| MX (1) | MX2022005563A (es) |
| PH (1) | PH12022551105A1 (es) |
| TW (1) | TWI882032B (es) |
| UA (1) | UA129894C2 (es) |
| WO (1) | WO2021092246A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102850357B1 (ko) | 2018-10-22 | 2025-08-27 | 알루미스 인크. | Tyk2 억제제 및 이의 용도 |
| BR112021015616A2 (pt) * | 2019-02-07 | 2021-11-09 | Ventyx Biosciences Inc | Ligantes de pseudoquinase tyk2 |
| AU2020239026B2 (en) * | 2019-03-11 | 2025-10-09 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| BR112021019070A2 (pt) | 2019-03-26 | 2022-02-15 | Ventyx Biosciences Inc | Ligantes de pseudoquinase tyk2 |
| US11753411B2 (en) | 2019-11-08 | 2023-09-12 | Ventyx Biosciences, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands |
| CN115209952B (zh) | 2020-01-13 | 2025-05-30 | 维基分析有限公司 | 经取代的吡唑并嘧啶及其用途 |
| US20250051338A1 (en) | 2021-10-25 | 2025-02-13 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| CN119816502A (zh) * | 2022-07-06 | 2025-04-11 | 温缇克斯生物科学公司 | Tyk2抑制剂的结晶形式 |
| EP4649082A1 (en) * | 2023-01-13 | 2025-11-19 | Ventyx Biosciences, Inc. | Preparation of a tyk2 inhibitor |
| CN117247389A (zh) * | 2023-09-18 | 2023-12-19 | 南京友怡医药科技有限公司 | 一种靶向药物化合物及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| MXPA05008955A (es) | 2003-02-28 | 2006-02-22 | Teijin Pharma Ltd | Derivados de pirazolo [1,5-a] pirimidina. |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| TWI421078B (zh) | 2005-10-06 | 2014-01-01 | Merck Sharp & Dohme | 關卡激酶抑制劑及其用途 |
| WO2010118207A1 (en) * | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
| CN105693720B (zh) | 2010-05-20 | 2019-01-18 | 阵列生物制药公司 | 作为trk激酶抑制剂的大环化合物 |
| US10065963B2 (en) | 2015-11-06 | 2018-09-04 | Incyte Corporation | Heterocyclic compounds as PI3K-γ inhibitors |
| KR102477063B1 (ko) | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 |
| IL269036B2 (en) | 2017-03-08 | 2023-03-01 | Nimbus Lakshmi Inc | tyk2 inhibitors, uses and methods for their production |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| SG11201910197SA (en) | 2017-05-15 | 2019-11-28 | Dana Farber Cancer Inst Inc | Compounds for treating dengue virus infection and other viral infections |
| US11046698B2 (en) | 2017-07-28 | 2021-06-29 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| US11891400B2 (en) | 2018-09-10 | 2024-02-06 | Eli Lilly And Company | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus |
| US11414431B2 (en) | 2018-10-15 | 2022-08-16 | Nimbus Lakshmi, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors |
| TWI800696B (zh) | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| BR112021015616A2 (pt) | 2019-02-07 | 2021-11-09 | Ventyx Biosciences Inc | Ligantes de pseudoquinase tyk2 |
| AU2020239026B2 (en) | 2019-03-11 | 2025-10-09 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| BR112021019070A2 (pt) | 2019-03-26 | 2022-02-15 | Ventyx Biosciences Inc | Ligantes de pseudoquinase tyk2 |
| US11753411B2 (en) | 2019-11-08 | 2023-09-12 | Ventyx Biosciences, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands |
-
2020
- 2020-11-05 US US17/090,805 patent/US11753411B2/en active Active
- 2020-11-05 WO PCT/US2020/059210 patent/WO2021092246A1/en not_active Ceased
- 2020-11-05 CA CA3160637A patent/CA3160637A1/en active Pending
- 2020-11-05 TW TW109138709A patent/TWI882032B/zh active
- 2020-11-05 AU AU2020378345A patent/AU2020378345A1/en active Pending
- 2020-11-05 MX MX2022005563A patent/MX2022005563A/es unknown
- 2020-11-05 CN CN202080092581.XA patent/CN114929226B/zh active Active
- 2020-11-05 UA UAA202201178A patent/UA129894C2/uk unknown
- 2020-11-05 PH PH1/2022/551105A patent/PH12022551105A1/en unknown
- 2020-11-05 BR BR112022008821A patent/BR112022008821A2/pt unknown
- 2020-11-05 JP JP2022525957A patent/JP7635228B2/ja active Active
- 2020-11-05 KR KR1020227018394A patent/KR20220107194A/ko active Pending
- 2020-11-05 IL IL292785A patent/IL292785B2/en unknown
- 2020-11-05 EP EP20884019.9A patent/EP4054581A4/en active Pending
-
2022
- 2022-05-04 CL CL2022001178A patent/CL2022001178A1/es unknown
- 2022-06-01 CO CONC2022/0007814A patent/CO2022007814A2/es unknown
-
2023
- 2023-07-06 US US18/348,296 patent/US20230348478A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022007814A2 (es) | 2022-09-09 |
| TWI882032B (zh) | 2025-05-01 |
| US20230348478A1 (en) | 2023-11-02 |
| AU2020378345A1 (en) | 2022-06-02 |
| KR20220107194A (ko) | 2022-08-02 |
| EP4054581A4 (en) | 2023-11-22 |
| UA129894C2 (uk) | 2025-09-03 |
| CN114929226B (zh) | 2024-09-27 |
| US11753411B2 (en) | 2023-09-12 |
| CN114929226A (zh) | 2022-08-19 |
| WO2021092246A1 (en) | 2021-05-14 |
| IL292785B2 (en) | 2025-09-01 |
| JP7635228B2 (ja) | 2025-02-25 |
| CL2022001178A1 (es) | 2023-02-03 |
| US20210139486A1 (en) | 2021-05-13 |
| PH12022551105A1 (en) | 2023-11-20 |
| CA3160637A1 (en) | 2021-05-14 |
| JP2022553841A (ja) | 2022-12-26 |
| BR112022008821A2 (pt) | 2022-08-23 |
| IL292785A (en) | 2022-07-01 |
| IL292785B1 (en) | 2025-05-01 |
| EP4054581A1 (en) | 2022-09-14 |
| TW202128698A (zh) | 2021-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
| MX2021009555A (es) | Ligandos de pseudocinasa tyk2. | |
| MX2025003876A (es) | Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina | |
| MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
| EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
| MX2022000712A (es) | Moduladores de nlrp3. | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| MX2021013602A (es) | Inhibidores de jak. | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| MX2021002916A (es) | Pirfenidona enriquecida con deuterio y métodos para su uso. | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| MX2021008941A (es) | Moduladores gpr35. | |
| EA201990399A1 (ru) | Соединения, композиции и их применение |